Clarivate Releases 2022 Drugs to Watch List

Clarivate has released their 2022 Drugs to Watch list. The list includes seven experimental therapeutics in the pipeline that have the potential to advance public health and become heavy hitters for pharma. These drugs include lecanemab, an Alzheimer’s drug, adagrasib, a cancer drug, and the type 2 diabetes drug tirzepatide.

According to Clarivate, “Drugs to Watch identifies treatments entering the market that have potential to realize $1 billion USD annual sales within five years, based on interviews with therapy experts; Disease Landscape & Forecast reports; Cortellis™ sales data; and other industry sources.”

Click here to learn more about all 7 drugs and their market and public health potential.

(Source: Clarivate, January 18^th, 2022)